Use of pentoxifylline in treatment of children with dengue hemorrhagic fever

Pediatric Infectious Disease Journal

Volumn 31, Issue 7, 2012, Pages 771-773

  Salgado, Doris ^a   Zabaleta, Tatiana Esther ^a   Hatch, Steven ^b   Vega, Marta Rocio ^a   Rodriguez, Jairo ^a  

^a UNIVERSIDAD SURCOLOMBIANA   (Colombia)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Dengue; Dengue hemorrhagic fever; Inflammatory cytokines; Pentoxifylline; Plasma leakage

Indexed keywords

PENTOXIFYLLINE;

ADOLESCENT; ARTICLE; CHILD; CONTROLLED STUDY; DENGUE; DISEASE COURSE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; HOSPITAL ADMISSION; HUMAN; INFANT; INTENSIVE CARE; LENGTH OF STAY; MAJOR CLINICAL STUDY; PILOT STUDY; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; DENGUE HEMORRHAGIC FEVER; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INFANT; MALE; PENTOXIFYLLINE; PROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84862764153     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3182575e6a     Document Type: Article

References (13)

1. Salgado DM, Rodríguez JA, Garzón M, et al. [Clinical and epidemiological characterisation of dengue haemorrhagic fever in Neiva, Colombia, 2004]. Rev Salud Publica (Bogota). 2007;9:53-63.
2. Green S, Vaughn DW, Kalayanarooj S, et al. Early immune activation in acute dengue illness is related to development of plasma leakage and disease severity. J Infect Dis. 1999;179:755-762. (Pubitemid 29159319)
3. Mangada MM, Rothman AL. Altered cytokine responses of dengue-specific CD4+ T cells to heterologous serotypes. J Immunol. 2005;175:2676-2683. (Pubitemid 41113883)
4. Schönharting M, Musikic P, Müller R. The haemorheological and antithrombotic potential of pentoxifylline ("Trental"): a review. Pharmatherapeutica. 1988;5:159-169. (Pubitemid 18054310)
5. Atrasheuskaya A, Petzelbauer P, Fredeking TM, et al. Anti-TNF antibody treatment reduces mortality in experimental dengue virus infection. FEMS Immunol Med Microbiol. 2003;35:33-42. (Pubitemid 36173502)
6. Ward A, Clissold SP. Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs. 1987;34:50-97. (Pubitemid 17092322)
7. Coimbra R, Melbostad H, Hoyt DB. Effects of phosphodiesterase inhibition on the inflammatory response after shock: role of pentoxifylline. J Trauma. 2004;56:442-449. (Pubitemid 38295396)
8. Berman B, Wietzerbin J, Sanceau J, et al. Pentoxifylline inhibits certain constitutive and tumor necrosis factor-alpha-induced activities of human normal dermal fibroblasts. J Invest Dermatol. 1992;98:706-712.
9. Adel M, Awad HA, Abdel-Naim AB, et al. Effects of pentoxifylline on coagulation profile and disseminated intravascular coagulation incidence in Egyptian septic neonates. J Clin Pharm Ther. 2010;35:257-265.
10. Lauterbach R, Pawlik D, Kowalczyk D, et al. Effect of the immunomodulating agent, pentoxifylline, in the treatment of sepsis in prematurely delivered infants: a placebo-controlled, double-blind trial. Crit Care Med. 1999;27:807-814. (Pubitemid 29218217)
11. Balaforlu B, Eskiyoruk I, Kus B, et al. Seasonal variation of C-reactive protein and atherosclerotic cardiovascular events in hemodialysis patients. Ren Fail. 2010;32:825-831.
12. Lannergård A, Viberg A, Cars O, et al. The time course of body temperature, serum amyloid A protein, C-reactive protein and interleukin-6 in patients with bacterial infection during the initial 3 days of antibiotic therapy. Scand J Infect Dis. 2009;41:663-671.
13. World Health Organization. Dengue: Guidelines for Diagnosis, Treatment, Prevention and Control. Geneva, Switzerland: World Health Organization; 2009.